STOCK TITAN

[8-K] HeartSciences Inc. Warrant Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

BranchOut Food Inc. (Nasdaq: BOF) has filed a Rule 424(b)(3) resale prospectus covering up to 8,045,748 shares of common stock held or acquirable by 30+ selling stockholders. The shares consist of (i) 1,827,429 outstanding shares, (ii) 4,484,305 shares issuable upon conversion of a $3.4 million 12% senior secured convertible note held by Kaufman Kapital LLC at a fixed conversion price of $0.7582, and (iii) 1,734,014 shares issuable from multiple warrant classes with exercise prices ranging from $0.96 to $7.50.

The company itself is not issuing new shares and will receive no proceeds; selling stockholders will bear selling commissions, while BranchOut will cover registration expenses. If all convertible securities are exercised/converted, shares outstanding would rise from 10,719,769 to 16,938,088, a potential dilution of roughly 58%.

Capital structure & recent financings: Since January 2024 the company has raised cash through (1) senior secured promissory notes totaling $1.675 million (15%–rate, warrants at $1.00), (2) a private placement of $3.4 million in convertible debt to Kaufman Kapital, and (3) an insider unit offering generating $0.525 million. Kaufman Kapital also exercised 1 million $1.00 warrants for $1.0 million cash and holds an additional 500 k $1.50 warrants expiring 12/31/26. Note and warrant maturities were recently extended, and liens on “substantially all assets” are pari passu with earlier senior notes.

Business context: BranchOut produces plant-based dehydrated snacks and ingredients using proprietary REV dehydration technology licensed from EnWave. A new vertically integrated Peruvian facility with three large-scale REV machines commenced operations in December 2024; management expects higher operating margins in 2025 as production shifts in-house.

Key risk highlighted: Large-scale secondary sales could pressure the stock; merely registering the shares may create an overhang even if stockholders defer selling. Additional risks are incorporated by reference to prior SEC filings.

BOF last traded at $2.69 on 10 July 2025; the fixed conversion price of the note ($0.7582) and low exercise prices for many warrants are deeply in-the-money, underscoring potential dilution.

BranchOut Food Inc. (Nasdaq: BOF) ha depositato un prospetto di rivendita ai sensi della Rule 424(b)(3) relativo a un massimo di 8.045.748 azioni ordinarie detenute o acquisibili da oltre 30 azionisti venditori. Le azioni comprendono (i) 1.827.429 azioni in circolazione, (ii) 4.484.305 azioni emettibili a seguito della conversione di una nota convertibile senior garantita al 12% per 3,4 milioni di dollari detenuta da Kaufman Kapital LLC a un prezzo di conversione fisso di 0,7582$, e (iii) 1.734.014 azioni emettibili da diverse classi di warrant con prezzi di esercizio compresi tra 0,96$ e 7,50$.

L’azienda stessa non emette nuove azioni e non riceverà proventi; le commissioni di vendita saranno a carico degli azionisti venditori, mentre BranchOut coprirà le spese di registrazione. Se tutte le securities convertibili verranno esercitate/convertite, le azioni in circolazione aumenterebbero da 10.719.769 a 16.938.088, con una potenziale diluizione di circa il 58%.

Struttura del capitale e finanziamenti recenti: Da gennaio 2024 la società ha raccolto liquidità tramite (1) note promissorie senior garantite per un totale di 1,675 milioni di dollari (tasso 15%, warrant a 1,00$), (2) un collocamento privato di debito convertibile da 3,4 milioni di dollari a Kaufman Kapital, e (3) un’offerta interna di unità che ha generato 0,525 milioni di dollari. Kaufman Kapital ha inoltre esercitato 1 milione di warrant a 1,00$ per 1,0 milione di dollari in contanti e detiene ulteriori 500.000 warrant a 1,50$ con scadenza 31/12/2026. Le scadenze di note e warrant sono state recentemente estese e i privilegi su “quasi tutti gli asset” sono pari passu con note senior precedenti.

Contesto aziendale: BranchOut produce snack e ingredienti disidratati a base vegetale utilizzando la tecnologia proprietaria di disidratazione REV concessa in licenza da EnWave. Un nuovo stabilimento integrato verticalmente in Perù con tre macchine REV di grande scala ha iniziato le operazioni a dicembre 2024; la direzione prevede margini operativi più elevati nel 2025 grazie allo spostamento della produzione internamente.

Rischio chiave evidenziato: Vendite secondarie su larga scala potrebbero esercitare pressione sul titolo; la semplice registrazione delle azioni potrebbe creare un effetto ombra anche se gli azionisti rinviassero la vendita. Ulteriori rischi sono richiamati per riferimento nelle precedenti comunicazioni SEC.

BOF ha chiuso l’ultima quotazione a 2,69$ il 10 luglio 2025; il prezzo di conversione fisso della nota (0,7582$) e i bassi prezzi di esercizio di molti warrant sono fortemente in-the-money, sottolineando il rischio di diluizione.

BranchOut Food Inc. (Nasdaq: BOF) ha presentado un prospecto de reventa bajo la Regla 424(b)(3) que cubre hasta 8.045.748 acciones ordinarias en poder o adquiribles por más de 30 accionistas vendedores. Las acciones incluyen (i) 1.827.429 acciones en circulación, (ii) 4.484.305 acciones que se emitirán tras la conversión de una nota convertible senior garantizada al 12% por 3,4 millones de dólares en poder de Kaufman Kapital LLC a un precio fijo de conversión de 0,7582$, y (iii) 1.734.014 acciones emitibles a partir de varias clases de warrants con precios de ejercicio entre 0,96$ y 7,50$.

La compañía no está emitiendo nuevas acciones ni recibirá ingresos; las comisiones de venta correrán por cuenta de los accionistas vendedores, mientras que BranchOut cubrirá los gastos de registro. Si se ejercen o convierten todos los valores convertibles, las acciones en circulación aumentarían de 10.719.769 a 16.938.088, una posible dilución de aproximadamente el 58%.

Estructura de capital y financiamientos recientes: Desde enero de 2024, la empresa ha recaudado efectivo a través de (1) pagarés senior garantizados por un total de 1,675 millones de dólares (tasa 15%, warrants a 1,00$), (2) una colocación privada de deuda convertible por 3,4 millones de dólares a Kaufman Kapital, y (3) una oferta interna de unidades que generó 0,525 millones de dólares. Kaufman Kapital también ejerció 1 millón de warrants a 1,00$ por 1,0 millón de dólares en efectivo y posee otros 500.000 warrants a 1,50$ que vencen el 31/12/2026. Los vencimientos de notas y warrants se extendieron recientemente y los gravámenes sobre “prácticamente todos los activos” son pari passu con notas senior anteriores.

Contexto empresarial: BranchOut produce snacks e ingredientes deshidratados a base de plantas utilizando la tecnología propietaria de deshidratación REV licenciada por EnWave. Una nueva planta integrada verticalmente en Perú con tres máquinas REV de gran escala comenzó operaciones en diciembre de 2024; la dirección espera márgenes operativos más altos en 2025 a medida que la producción se internalice.

Riesgo clave destacado: Las ventas secundarias a gran escala podrían presionar la acción; el simple registro de las acciones puede crear una sobreoferta incluso si los accionistas retrasan la venta. Riesgos adicionales se incorporan por referencia a presentaciones anteriores ante la SEC.

BOF se negoció por última vez a 2,69$ el 10 de julio de 2025; el precio fijo de conversión de la nota (0,7582$) y los bajos precios de ejercicio de muchos warrants están muy dentro del dinero, subrayando la potencial dilución.

BranchOut Food Inc. (나스닥: BOF)는 30명 이상의 판매 주주가 보유하거나 취득할 수 있는 8,045,748주의 보통주에 대한 Rule 424(b)(3) 재판매 설명서를 제출했습니다. 주식은 (i) 1,827,429주의 발행 주식, (ii) Kaufman Kapital LLC가 보유한 340만 달러 12% 선순위 담보 전환사채의 전환으로 발행 가능한 4,484,305주(전환 가격 고정 0.7582달러), (iii) 행사 가격이 0.96달러에서 7.50달러 사이인 여러 워런트 클래스에서 발행 가능한 1,734,014주로 구성됩니다.

회사는 신규 주식을 발행하지 않으며 수익도 받지 않습니다; 판매 주주가 판매 수수료를 부담하고 BranchOut은 등록 비용을 부담합니다. 모든 전환 증권이 행사/전환되면 발행 주식 수는 10,719,769주에서 16,938,088주로 증가하여 약 58%의 희석 효과가 발생할 수 있습니다.

자본 구조 및 최근 자금 조달: 2024년 1월 이후 회사는 (1) 총 167만 5천 달러(금리 15%, 워런트 행사 가격 1.00달러)의 선순위 담보 약속어음, (2) Kaufman Kapital에 대한 340만 달러 전환 부채의 사모 발행, (3) 내부자 단위 공모를 통해 52만 5천 달러를 조달했습니다. Kaufman Kapital은 또한 100만 개의 1.00달러 워런트를 행사하여 100만 달러 현금을 확보했으며, 2026년 12월 31일 만료되는 추가 50만 개의 1.50달러 워런트를 보유하고 있습니다. 어음 및 워런트 만기는 최근 연장되었으며, “실질적으로 모든 자산”에 대한 담보권은 이전 선순위 어음과 동등한 순위입니다.

사업 배경: BranchOut은 EnWave로부터 라이선스 받은 독점 REV 탈수 기술을 사용하여 식물성 탈수 스낵 및 원료를 생산합니다. 2024년 12월에 세 대의 대형 REV 기계가 가동되는 페루의 새로 통합된 수직 공장이 가동을 시작했으며, 경영진은 2025년에는 생산 내재화로 인해 운영 마진이 상승할 것으로 기대하고 있습니다.

주요 위험 요인: 대규모 2차 매도는 주가에 압력을 가할 수 있으며, 단순히 주식을 등록하는 것만으로도 주주들이 매도를 미루더라도 과잉 공급 우려가 생길 수 있습니다. 추가 위험은 이전 SEC 제출 자료를 통해 참조됩니다.

BOF의 마지막 거래 가격은 2025년 7월 10일에 2.69달러였으며, 어음의 고정 전환 가격(0.7582달러)과 많은 워런트의 낮은 행사 가격은 깊은 인더머니 상태로, 잠재적 희석을 강조합니다.

BranchOut Food Inc. (Nasdaq : BOF) a déposé un prospectus de revente selon la règle 424(b)(3) couvrant jusqu'à 8 045 748 actions ordinaires détenues ou pouvant être acquises par plus de 30 actionnaires vendeurs. Les actions comprennent (i) 1 827 429 actions en circulation, (ii) 4 484 305 actions pouvant être émises lors de la conversion d'une obligation convertible senior garantie à 12 % d’un montant de 3,4 millions de dollars détenue par Kaufman Kapital LLC à un prix de conversion fixe de 0,7582 $, et (iii) 1 734 014 actions pouvant être émises à partir de plusieurs catégories de bons de souscription avec des prix d’exercice allant de 0,96 $ à 7,50 $.

La société elle-même n’émet pas de nouvelles actions et ne recevra aucun produit ; les commissions de vente seront à la charge des actionnaires vendeurs, tandis que BranchOut prendra en charge les frais d’enregistrement. Si tous les titres convertibles sont exercés/convertis, le nombre d’actions en circulation passerait de 10 719 769 à 16 938 088, soit une dilution potentielle d’environ 58 %.

Structure du capital et financements récents : Depuis janvier 2024, la société a levé des fonds via (1) des billets de premier rang garantis totalisant 1,675 million de dollars (taux de 15 %, bons de souscription à 1,00 $), (2) un placement privé de dette convertible de 3,4 millions de dollars auprès de Kaufman Kapital, et (3) une offre interne d’unités générant 0,525 million de dollars. Kaufman Kapital a également exercé 1 million de bons de souscription à 1,00 $ pour 1,0 million de dollars en numéraire et détient 500 000 autres bons à 1,50 $ expirant le 31/12/2026. Les échéances des billets et des bons ont récemment été prolongées, et les privilèges sur « pratiquement tous les actifs » sont pari passu avec les billets senior antérieurs.

Contexte commercial : BranchOut produit des snacks et ingrédients déshydratés à base de plantes en utilisant la technologie propriétaire de déshydratation REV sous licence d’EnWave. Une nouvelle usine intégrée verticalement au Pérou avec trois grandes machines REV a commencé ses opérations en décembre 2024 ; la direction prévoit des marges opérationnelles plus élevées en 2025 à mesure que la production sera internalisée.

Risque clé souligné : Des ventes secondaires à grande échelle pourraient exercer une pression sur le titre ; le simple enregistrement des actions pourrait créer un surcroît d’offre même si les actionnaires retardent la vente. Des risques supplémentaires sont intégrés par référence aux dépôts antérieurs auprès de la SEC.

BOF a été échangé pour la dernière fois à 2,69 $ le 10 juillet 2025 ; le prix de conversion fixe de l’obligation (0,7582 $) et les faibles prix d’exercice de nombreux bons sont profondément dans la monnaie, soulignant une dilution potentielle.

BranchOut Food Inc. (Nasdaq: BOF) hat einen Rule 424(b)(3) Wiederverkaufsprospekt eingereicht, der bis zu 8.045.748 Aktien von Stammaktien umfasst, die von über 30 verkaufenden Aktionären gehalten oder erworben werden können. Die Aktien setzen sich zusammen aus (i) 1.827.429 ausstehenden Aktien, (ii) 4.484.305 Aktien, die bei Umwandlung einer 3,4 Millionen US-Dollar 12% Senior besicherten Wandelanleihe der Kaufman Kapital LLC zu einem festen Wandlungspreis von 0,7582 USD ausgegeben werden, und (iii) 1.734.014 Aktien, die aus mehreren Warrants mit Ausübungspreisen zwischen 0,96 USD und 7,50 USD ausgegeben werden können.

Das Unternehmen selbst gibt keine neuen Aktien aus und erhält keine Erlöse; die verkaufenden Aktionäre tragen die Verkaufsprovisionen, während BranchOut die Registrierungskosten übernimmt. Wenn alle wandelbaren Wertpapiere ausgeübt/umgewandelt werden, würde die Anzahl der ausstehenden Aktien von 10.719.769 auf 16.938.088 steigen, was einer potenziellen Verwässerung von etwa 58 % entspricht.

Kapitalstruktur & jüngste Finanzierungen: Seit Januar 2024 hat das Unternehmen Kapital durch (1) Senior besicherte Schuldscheine in Höhe von insgesamt 1,675 Millionen USD (15 % Zins, Warrants zu 1,00 USD), (2) eine Privatplatzierung von 3,4 Millionen USD wandelbarer Schulden an Kaufman Kapital und (3) ein Insider-Unit-Angebot, das 0,525 Millionen USD einbrachte, aufgenommen. Kaufman Kapital hat außerdem 1 Million Warrants zu 1,00 USD ausgeübt und hält weitere 500.000 Warrants zu 1,50 USD mit Ablauf am 31.12.2026. Laufzeiten von Schuldscheinen und Warrants wurden kürzlich verlängert, und Pfandrechte auf „praktisch alle Vermögenswerte“ sind pari passu mit früheren Senior Notes.

Geschäftskontext: BranchOut produziert pflanzenbasierte dehydrierte Snacks und Zutaten unter Verwendung der firmeneigenen REV-Dehydrierungstechnologie, die von EnWave lizenziert ist. Eine neue vertikal integrierte Anlage in Peru mit drei großmaßstäblichen REV-Maschinen nahm im Dezember 2024 den Betrieb auf; das Management erwartet für 2025 höhere operative Margen, da die Produktion intern verlagert wird.

Hervorgehobenes Hauptrisiko: Großvolumige Sekundärverkäufe könnten den Aktienkurs unter Druck setzen; allein die Registrierung der Aktien könnte eine Überhangsituation schaffen, selbst wenn Aktionäre den Verkauf aufschieben. Weitere Risiken sind durch Verweis auf frühere SEC-Einreichungen einbezogen.

BOF wurde zuletzt am 10. Juli 2025 zu 2,69 USD gehandelt; der feste Wandlungspreis der Note (0,7582 USD) und die niedrigen Ausübungspreise vieler Warrants sind tief im Geld, was auf eine potenzielle Verwässerung hinweist.

Positive
  • Vertical integration: Newly completed Peru facility with three REV machines is expected to improve operating margins in 2025.
  • Exclusive technology rights: Licensed REV dehydration patent portfolio positions BOF as a first mover in avocado and banana snack segments.
  • $1 million cash infusion from Kaufman Kapital’s warrant exercise enhances near-term liquidity without additional dilution.
Negative
  • Potential 58% dilution if all registered shares enter the market, expanding float from 10.7 M to 16.9 M.
  • Share overhang of 8.0 M newly tradable shares may pressure price and increase volatility.
  • High-cost secured debt: 12%–15% notes secured by substantially all assets add balance-sheet risk.
  • Deeply in-the-money conversion price of $0.7582 incentivizes rapid conversion and selling.
  • Covenant limitations restrict early repayment of convertible note, extending leverage through 2026.

Insights

TL;DR Registration enables insiders and lenders to sell ~58% additional shares, creating overhang; no new capital enters the company.

The prospectus is structurally negative for existing shareholders. While the note exercise already provided $1 million, the bulk of securities being registered were previously issued and convert at $0.7582, far below the market price. Conversion would nearly double float and could cap upside as holders monetize gains. The company’s strategic move to vertically integrate production is fundamentally positive, but those benefits do not offset the immediate supply risk posed by 8 million freely tradable shares. Secured debt at 12-15% and cross-collateralized liens add leverage risk if operating improvements lag. Because the filing does not raise fresh funds, it has limited positive impact on liquidity yet increases dilution pressure. I classify the net market effect as moderately negative.

TL;DR High insider participation and secured debt covenants heighten governance and dilution concerns.

The filing reveals significant related-party transactions: executives (CEO, CFO, President) bought units and hold large warrant positions, while CFO-affiliated Eagle Vision receives fees and collateral agency roles. Kaufman Kapital’s liens on ‘substantially all assets’ and restrictions on prepaying its note subordinate other stakeholders. Extension of maturities to 2026 increases long-term leverage exposure. Although transparent disclosure meets SEC requirements, concentrated control of conversion rights could influence share supply timing. Overall governance risk is elevated, especially given the relatively small current float. Investors should monitor debt covenant compliance and insider selling patterns after the prospectus is declared effective.

BranchOut Food Inc. (Nasdaq: BOF) ha depositato un prospetto di rivendita ai sensi della Rule 424(b)(3) relativo a un massimo di 8.045.748 azioni ordinarie detenute o acquisibili da oltre 30 azionisti venditori. Le azioni comprendono (i) 1.827.429 azioni in circolazione, (ii) 4.484.305 azioni emettibili a seguito della conversione di una nota convertibile senior garantita al 12% per 3,4 milioni di dollari detenuta da Kaufman Kapital LLC a un prezzo di conversione fisso di 0,7582$, e (iii) 1.734.014 azioni emettibili da diverse classi di warrant con prezzi di esercizio compresi tra 0,96$ e 7,50$.

L’azienda stessa non emette nuove azioni e non riceverà proventi; le commissioni di vendita saranno a carico degli azionisti venditori, mentre BranchOut coprirà le spese di registrazione. Se tutte le securities convertibili verranno esercitate/convertite, le azioni in circolazione aumenterebbero da 10.719.769 a 16.938.088, con una potenziale diluizione di circa il 58%.

Struttura del capitale e finanziamenti recenti: Da gennaio 2024 la società ha raccolto liquidità tramite (1) note promissorie senior garantite per un totale di 1,675 milioni di dollari (tasso 15%, warrant a 1,00$), (2) un collocamento privato di debito convertibile da 3,4 milioni di dollari a Kaufman Kapital, e (3) un’offerta interna di unità che ha generato 0,525 milioni di dollari. Kaufman Kapital ha inoltre esercitato 1 milione di warrant a 1,00$ per 1,0 milione di dollari in contanti e detiene ulteriori 500.000 warrant a 1,50$ con scadenza 31/12/2026. Le scadenze di note e warrant sono state recentemente estese e i privilegi su “quasi tutti gli asset” sono pari passu con note senior precedenti.

Contesto aziendale: BranchOut produce snack e ingredienti disidratati a base vegetale utilizzando la tecnologia proprietaria di disidratazione REV concessa in licenza da EnWave. Un nuovo stabilimento integrato verticalmente in Perù con tre macchine REV di grande scala ha iniziato le operazioni a dicembre 2024; la direzione prevede margini operativi più elevati nel 2025 grazie allo spostamento della produzione internamente.

Rischio chiave evidenziato: Vendite secondarie su larga scala potrebbero esercitare pressione sul titolo; la semplice registrazione delle azioni potrebbe creare un effetto ombra anche se gli azionisti rinviassero la vendita. Ulteriori rischi sono richiamati per riferimento nelle precedenti comunicazioni SEC.

BOF ha chiuso l’ultima quotazione a 2,69$ il 10 luglio 2025; il prezzo di conversione fisso della nota (0,7582$) e i bassi prezzi di esercizio di molti warrant sono fortemente in-the-money, sottolineando il rischio di diluizione.

BranchOut Food Inc. (Nasdaq: BOF) ha presentado un prospecto de reventa bajo la Regla 424(b)(3) que cubre hasta 8.045.748 acciones ordinarias en poder o adquiribles por más de 30 accionistas vendedores. Las acciones incluyen (i) 1.827.429 acciones en circulación, (ii) 4.484.305 acciones que se emitirán tras la conversión de una nota convertible senior garantizada al 12% por 3,4 millones de dólares en poder de Kaufman Kapital LLC a un precio fijo de conversión de 0,7582$, y (iii) 1.734.014 acciones emitibles a partir de varias clases de warrants con precios de ejercicio entre 0,96$ y 7,50$.

La compañía no está emitiendo nuevas acciones ni recibirá ingresos; las comisiones de venta correrán por cuenta de los accionistas vendedores, mientras que BranchOut cubrirá los gastos de registro. Si se ejercen o convierten todos los valores convertibles, las acciones en circulación aumentarían de 10.719.769 a 16.938.088, una posible dilución de aproximadamente el 58%.

Estructura de capital y financiamientos recientes: Desde enero de 2024, la empresa ha recaudado efectivo a través de (1) pagarés senior garantizados por un total de 1,675 millones de dólares (tasa 15%, warrants a 1,00$), (2) una colocación privada de deuda convertible por 3,4 millones de dólares a Kaufman Kapital, y (3) una oferta interna de unidades que generó 0,525 millones de dólares. Kaufman Kapital también ejerció 1 millón de warrants a 1,00$ por 1,0 millón de dólares en efectivo y posee otros 500.000 warrants a 1,50$ que vencen el 31/12/2026. Los vencimientos de notas y warrants se extendieron recientemente y los gravámenes sobre “prácticamente todos los activos” son pari passu con notas senior anteriores.

Contexto empresarial: BranchOut produce snacks e ingredientes deshidratados a base de plantas utilizando la tecnología propietaria de deshidratación REV licenciada por EnWave. Una nueva planta integrada verticalmente en Perú con tres máquinas REV de gran escala comenzó operaciones en diciembre de 2024; la dirección espera márgenes operativos más altos en 2025 a medida que la producción se internalice.

Riesgo clave destacado: Las ventas secundarias a gran escala podrían presionar la acción; el simple registro de las acciones puede crear una sobreoferta incluso si los accionistas retrasan la venta. Riesgos adicionales se incorporan por referencia a presentaciones anteriores ante la SEC.

BOF se negoció por última vez a 2,69$ el 10 de julio de 2025; el precio fijo de conversión de la nota (0,7582$) y los bajos precios de ejercicio de muchos warrants están muy dentro del dinero, subrayando la potencial dilución.

BranchOut Food Inc. (나스닥: BOF)는 30명 이상의 판매 주주가 보유하거나 취득할 수 있는 8,045,748주의 보통주에 대한 Rule 424(b)(3) 재판매 설명서를 제출했습니다. 주식은 (i) 1,827,429주의 발행 주식, (ii) Kaufman Kapital LLC가 보유한 340만 달러 12% 선순위 담보 전환사채의 전환으로 발행 가능한 4,484,305주(전환 가격 고정 0.7582달러), (iii) 행사 가격이 0.96달러에서 7.50달러 사이인 여러 워런트 클래스에서 발행 가능한 1,734,014주로 구성됩니다.

회사는 신규 주식을 발행하지 않으며 수익도 받지 않습니다; 판매 주주가 판매 수수료를 부담하고 BranchOut은 등록 비용을 부담합니다. 모든 전환 증권이 행사/전환되면 발행 주식 수는 10,719,769주에서 16,938,088주로 증가하여 약 58%의 희석 효과가 발생할 수 있습니다.

자본 구조 및 최근 자금 조달: 2024년 1월 이후 회사는 (1) 총 167만 5천 달러(금리 15%, 워런트 행사 가격 1.00달러)의 선순위 담보 약속어음, (2) Kaufman Kapital에 대한 340만 달러 전환 부채의 사모 발행, (3) 내부자 단위 공모를 통해 52만 5천 달러를 조달했습니다. Kaufman Kapital은 또한 100만 개의 1.00달러 워런트를 행사하여 100만 달러 현금을 확보했으며, 2026년 12월 31일 만료되는 추가 50만 개의 1.50달러 워런트를 보유하고 있습니다. 어음 및 워런트 만기는 최근 연장되었으며, “실질적으로 모든 자산”에 대한 담보권은 이전 선순위 어음과 동등한 순위입니다.

사업 배경: BranchOut은 EnWave로부터 라이선스 받은 독점 REV 탈수 기술을 사용하여 식물성 탈수 스낵 및 원료를 생산합니다. 2024년 12월에 세 대의 대형 REV 기계가 가동되는 페루의 새로 통합된 수직 공장이 가동을 시작했으며, 경영진은 2025년에는 생산 내재화로 인해 운영 마진이 상승할 것으로 기대하고 있습니다.

주요 위험 요인: 대규모 2차 매도는 주가에 압력을 가할 수 있으며, 단순히 주식을 등록하는 것만으로도 주주들이 매도를 미루더라도 과잉 공급 우려가 생길 수 있습니다. 추가 위험은 이전 SEC 제출 자료를 통해 참조됩니다.

BOF의 마지막 거래 가격은 2025년 7월 10일에 2.69달러였으며, 어음의 고정 전환 가격(0.7582달러)과 많은 워런트의 낮은 행사 가격은 깊은 인더머니 상태로, 잠재적 희석을 강조합니다.

BranchOut Food Inc. (Nasdaq : BOF) a déposé un prospectus de revente selon la règle 424(b)(3) couvrant jusqu'à 8 045 748 actions ordinaires détenues ou pouvant être acquises par plus de 30 actionnaires vendeurs. Les actions comprennent (i) 1 827 429 actions en circulation, (ii) 4 484 305 actions pouvant être émises lors de la conversion d'une obligation convertible senior garantie à 12 % d’un montant de 3,4 millions de dollars détenue par Kaufman Kapital LLC à un prix de conversion fixe de 0,7582 $, et (iii) 1 734 014 actions pouvant être émises à partir de plusieurs catégories de bons de souscription avec des prix d’exercice allant de 0,96 $ à 7,50 $.

La société elle-même n’émet pas de nouvelles actions et ne recevra aucun produit ; les commissions de vente seront à la charge des actionnaires vendeurs, tandis que BranchOut prendra en charge les frais d’enregistrement. Si tous les titres convertibles sont exercés/convertis, le nombre d’actions en circulation passerait de 10 719 769 à 16 938 088, soit une dilution potentielle d’environ 58 %.

Structure du capital et financements récents : Depuis janvier 2024, la société a levé des fonds via (1) des billets de premier rang garantis totalisant 1,675 million de dollars (taux de 15 %, bons de souscription à 1,00 $), (2) un placement privé de dette convertible de 3,4 millions de dollars auprès de Kaufman Kapital, et (3) une offre interne d’unités générant 0,525 million de dollars. Kaufman Kapital a également exercé 1 million de bons de souscription à 1,00 $ pour 1,0 million de dollars en numéraire et détient 500 000 autres bons à 1,50 $ expirant le 31/12/2026. Les échéances des billets et des bons ont récemment été prolongées, et les privilèges sur « pratiquement tous les actifs » sont pari passu avec les billets senior antérieurs.

Contexte commercial : BranchOut produit des snacks et ingrédients déshydratés à base de plantes en utilisant la technologie propriétaire de déshydratation REV sous licence d’EnWave. Une nouvelle usine intégrée verticalement au Pérou avec trois grandes machines REV a commencé ses opérations en décembre 2024 ; la direction prévoit des marges opérationnelles plus élevées en 2025 à mesure que la production sera internalisée.

Risque clé souligné : Des ventes secondaires à grande échelle pourraient exercer une pression sur le titre ; le simple enregistrement des actions pourrait créer un surcroît d’offre même si les actionnaires retardent la vente. Des risques supplémentaires sont intégrés par référence aux dépôts antérieurs auprès de la SEC.

BOF a été échangé pour la dernière fois à 2,69 $ le 10 juillet 2025 ; le prix de conversion fixe de l’obligation (0,7582 $) et les faibles prix d’exercice de nombreux bons sont profondément dans la monnaie, soulignant une dilution potentielle.

BranchOut Food Inc. (Nasdaq: BOF) hat einen Rule 424(b)(3) Wiederverkaufsprospekt eingereicht, der bis zu 8.045.748 Aktien von Stammaktien umfasst, die von über 30 verkaufenden Aktionären gehalten oder erworben werden können. Die Aktien setzen sich zusammen aus (i) 1.827.429 ausstehenden Aktien, (ii) 4.484.305 Aktien, die bei Umwandlung einer 3,4 Millionen US-Dollar 12% Senior besicherten Wandelanleihe der Kaufman Kapital LLC zu einem festen Wandlungspreis von 0,7582 USD ausgegeben werden, und (iii) 1.734.014 Aktien, die aus mehreren Warrants mit Ausübungspreisen zwischen 0,96 USD und 7,50 USD ausgegeben werden können.

Das Unternehmen selbst gibt keine neuen Aktien aus und erhält keine Erlöse; die verkaufenden Aktionäre tragen die Verkaufsprovisionen, während BranchOut die Registrierungskosten übernimmt. Wenn alle wandelbaren Wertpapiere ausgeübt/umgewandelt werden, würde die Anzahl der ausstehenden Aktien von 10.719.769 auf 16.938.088 steigen, was einer potenziellen Verwässerung von etwa 58 % entspricht.

Kapitalstruktur & jüngste Finanzierungen: Seit Januar 2024 hat das Unternehmen Kapital durch (1) Senior besicherte Schuldscheine in Höhe von insgesamt 1,675 Millionen USD (15 % Zins, Warrants zu 1,00 USD), (2) eine Privatplatzierung von 3,4 Millionen USD wandelbarer Schulden an Kaufman Kapital und (3) ein Insider-Unit-Angebot, das 0,525 Millionen USD einbrachte, aufgenommen. Kaufman Kapital hat außerdem 1 Million Warrants zu 1,00 USD ausgeübt und hält weitere 500.000 Warrants zu 1,50 USD mit Ablauf am 31.12.2026. Laufzeiten von Schuldscheinen und Warrants wurden kürzlich verlängert, und Pfandrechte auf „praktisch alle Vermögenswerte“ sind pari passu mit früheren Senior Notes.

Geschäftskontext: BranchOut produziert pflanzenbasierte dehydrierte Snacks und Zutaten unter Verwendung der firmeneigenen REV-Dehydrierungstechnologie, die von EnWave lizenziert ist. Eine neue vertikal integrierte Anlage in Peru mit drei großmaßstäblichen REV-Maschinen nahm im Dezember 2024 den Betrieb auf; das Management erwartet für 2025 höhere operative Margen, da die Produktion intern verlagert wird.

Hervorgehobenes Hauptrisiko: Großvolumige Sekundärverkäufe könnten den Aktienkurs unter Druck setzen; allein die Registrierung der Aktien könnte eine Überhangsituation schaffen, selbst wenn Aktionäre den Verkauf aufschieben. Weitere Risiken sind durch Verweis auf frühere SEC-Einreichungen einbezogen.

BOF wurde zuletzt am 10. Juli 2025 zu 2,69 USD gehandelt; der feste Wandlungspreis der Note (0,7582 USD) und die niedrigen Ausübungspreise vieler Warrants sind tief im Geld, was auf eine potenzielle Verwässerung hinweist.

false 0001468492 0001468492 2025-07-09 2025-07-09 0001468492 us-gaap:CommonStockMember 2025-07-09 2025-07-09 0001468492 HSCSW:WarrantsMember 2025-07-09 2025-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 9, 2025

 

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

 

Texas   001-41422   26-1344466
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

550 Reserve Street, Suite 360    
Southlake, Texas   76092
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (682) 237-7781

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   HSCS   The NASDAQ Stock Market LLC
Warrants   HSCSW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

The information set forth in Item 5.02 below is incorporated herein by reference.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment No. 2 to the Company’s Equity Incentive Plan

 

On July 9, 2025, the Company’s Board of Directors (the “Board”) approved an amendment to the Company’s 2023 Equity Incentive Plan, as amended (the “EIP Amendment” and as amended, the “Plan”) to increase the maximum aggregate number of shares of the Company’s common stock, $0.001 par value per share (the “common stock”), that may be issued under the Plan to 1,000,000 shares of common stock (the “Plan Shares Increase Amendment”). The Plan Shares Increase Amendment shall be considered and voted upon the shareholders of the Company at the Company’s next annual meeting of shareholders.

 

RSUs and Option Awards

 

On July 9, 2025, the Compensation Committee of the Board (the “Compensation Committee”) amended existing cash bonus payment criteria and granted restricted stock unit awards to the Company’s executive officers. The restricted stock unit awards were issued pursuant to the Plan. Andrew Simpson, the Company’s Chief Executive Officer and Chairman of the Board of Directors, received 68,750 restricted stock units of the Company (the “RSUs”), and Mark Hilz, the Company’s Chief Operating Officer, Secretary and Director, received 56,250 RSUs. The RSUs shall vest immediately upon the earlier of (i) FDA clearance of the Company’s MyoVista Device (including AI algorithm) or (ii) the MyoVista Insights platform together with first AI algorithm. The RSUs shall also vest upon a Change of Control (as defined in each respective officer’s employment agreement).

 

On July 9, 2025, the Compensation Committee approved an award of stock options (the “Options”) to purchase shares of common stock to the Company’s executive officers as follows: 275,000 Options to Andrew Simpson, the Company’s President, Chief Executive Officer and Chairman of the Board of Directors, 225,000 Options to Mark Hilz, the Company’s Chief Operating Officer, Secretary and Director, and 25,000 Options to Danielle Watson, the Company’s Chief Financial Officer and Treasurer. Such Options were issued pursuant to the Plan, have an exercise price of $4.37 per share and will vest over three years, with one-third of the respective Options vesting on July 9, 2026 and the remaining two-thirds vesting in eight equal installments thereafter beginning on October 9, 2026 and on each subsequent three-month anniversary of such date. The vesting of these Options would accelerate upon the earlier of (i) FDA clearance of the Company’s MyoVista Device (including AI algorithm) or (ii) the MyoVista Insights platform together with first AI algorithm. These Options were awarded pursuant to the form of the Company’s standard Incentive Stock Option Agreement.

 

On July 9, 2025, the Compensation Committee also approved an award of 25,000 stock options (the “Director Options”) to purchase shares of common stock to each of the Company’s non-employee directors, Brian Szymczak, Bruce Brent and David R. Wells. The Director Options were issued pursuant to the Plan, have an exercise price of $4.37 per share, will vest as follows: one-fourth of the respective Director Options vested on October 9, 2025 and the remaining Director Options will vest in three equal installments thereafter on each subsequent three-month anniversary of such date.

 

1

 

Item 8.01 Other Events.

 

Regulation A Offering

 

As previously disclosed, on February 12, 2025, the Company filed an Offering Statement on Form 1-A (File No. 024-12572) (as amended and supplemented from time to time, the “Form 1-A”), with the U.S. Securities and Exchange Commission (the “SEC”) and which was qualified by the SEC on March 10, 2025, to register the offering of up to 4,285,714 units of the Company (the “Units”) at an offering price of $3.50 per Unit, for a maximum offering amount of $15,000,000 worth of Units (collectively, the “Offering”). Each Unit consists of one share of the Company’s Series D Preferred Stock (as defined below) and one warrant (each a “Warrant” and collectively the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $5.00 per share.

 

As of July 11, 2025, the Company has received a total of $1.7 million of gross proceeds, resulting in the issuance of 487,701 Units, as a result of several closings of the Offering. As of July 11, 2025, holders of 229,665 shares of Series D Preferred Stock received as part of the issued Units have elected to convert such shares of Series D Preferred Stock into 229,665 shares of common stock (the “Reg A Issuance”).

 

Debt Exchange

 

In addition, as of July 11, 2025, the Company has exchanged $855,000 of its unsecured promissory note issued to a certain third party in September 2024 for 233,229 shares of the Company’s common stock reducing the principal amount of such note by such amount (the “Debt Exchange”).

 

As a result of the Reg A Issuance and the Debt Exchange, there are 1,555,049 shares of common stock issued and outstanding as of July 11, 2025.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1*   Amendment No. 2 to the HeartSciences Inc. 2023 Equity Incentive Plan.
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

*Filed herewith.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HeartSciences Inc.
     
Date: July 14, 2025 By: /s/Andrew Simpson
 

Name:

Title:

Andrew Simpson

President, Chief Executive Officer and Chairman of the Board of Directors

 

 

3

 

 

FAQ

How many BranchOut Food (BOF) shares are being registered for resale?

Up to 8,045,748 shares, including common shares, convertible-note shares, and warrant shares.

Will BOF receive any proceeds from this resale prospectus?

No. All proceeds go to the selling stockholders; BOF only pays registration expenses.

What is the potential dilution to BOF shareholders?

If all securities convert/exercise, shares outstanding rise from 10.72 M to 16.94 M, roughly a 58% increase.

Who is Kaufman Kapital and what are its conversion terms?

Kaufman Kapital LLC holds a $3.4 M 12% convertible note convertible at $0.7582 and warrants for 1.5 M shares.

What is BOF’s latest share price compared to conversion prices?

As of 10 July 2025 BOF traded at $2.69, far above the note’s $0.7582 conversion price and $1.00–$1.50 warrant prices.

How might the new Peru facility affect BOF’s margins?

Management expects higher operating margins in 2025 as production shifts from third-party contractors to in-house REV machines.

What risks does the prospectus highlight?

Primary risk is that substantial share sales could adversely affect BOF’s stock price; additional risks are incorporated by reference.
HeartSciences Inc

NASDAQ:HSCSW

HSCSW Rankings

HSCSW Latest News

HSCSW Latest SEC Filings

HSCSW Stock Data

1.75M
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
SOUTHLAKE